FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	20540
wasnington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(First)

NY

51 ASTOR PLACE, 10TH FLOOR

(Street)
NEW YORK

(Middle)

10003

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						or Se	ection	30(h) of the	Investme	ent Co	ompany Ac	t of 194	0								
						. Issuer Name <b>and</b> Ticker or Trading Symbol <u>LianBio</u> [ LIAN ]															
(Last) 51 ASTO	,	First)	(Middle)				Date of Earliest Transaction (Month/Day/Year) 1/01/2021								Officer (give title Other (sp below) below)				specify		
(Street)	ORK N	NY	10003	4. If Ame			If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line)     Form filed by One Reporting Person     X Form filed by More than One Reporting Person							
(City)	(;	State)	(Zip)																		
		٦	Table I - No	on-D	eriva	tive S	Secu	urities Ad	quired	, Dis	sposed	of, or	Bene	ficially (	Owned						
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Ye			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and					6. Own Form: (D) or I (I) (Inst	Direct I ndirect I rr. 4)	. Nature of ndirect Beneficial Ownership					
									Code	v	Amount		(A) or (D)	Price	Transaction (Instr. 3 and	n(s) d 4)			(Instr. 4)		
Ordinary	Shares	ares		11	11/01/2021				P		120,000		A	\$15.5	7,153,885				See footnote <sup>(1)</sup>		
Ordinary	Shares			11/02/2021				P		100,000		A	\$13.5 <sup>(7)</sup>	7,253,885				See footnote <sup>(1)</sup>			
Ordinary	Shares			11	/03/2	021			С		3,715,	3,715,510 A		(5)	10,969,395				See footnote <sup>(1)</sup>		
Ordinary	Shares			11	/03/2	021			С		14,619,	500	A	(6)	25,588,895				See footnote <sup>(1)</sup>		
Ordinary	Shares			11	/03/2	021			С		14,619,	500	A	(6)	21,653,385				See footnote <sup>(2)</sup>		
Ordinary	Shares			11	/03/2	021			С		2,923,0	000	A	(6)	(6) 4,330,675				See footnote <sup>(3)</sup>		
Ordinary	inary Shares		11/03/2021				С		2,477,0	005	<b>A</b> (5)		2,477,005				See footnote <sup>(4)</sup>				
			Table II					ities Acc warrants							wned						
Derivative Conversion Date Security or Exercise (Month/Day/Year) in		3A. Deemed Execution Da if any (Month/Day/Y	Code (Instr.			Derivative I		6. Date Exercisa Expiration Date (Month/Day/Yea		9	Securities Underly		lerlying	8. Price of Derivative Security (Instr. 5)	9. Numb derivati Securiti Benefic Owned Followin Reporte	ve es ially ng	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)			
							Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Nur	ount or nber of tres		Transac (Instr. 4)			
Series A Preferred Shares	(5)	11/03/2021			С			635,369	(5)		(5)	Ordina Share		715,510	(5)	0	)	I	See footnote <sup>(1)</sup>		
Series Seed Preferred Shares	(6)	11/03/2021			С			2,500,000	(6)		(6)	Ordina Share		,619,500	(6)	0	١	I	See footnote <sup>(1)</sup>		
Series Seed Preferred Shares	(6)	11/03/2021			С			2,500,000	(6)		(6)	Ordina Share		,619,500	(6)	0	١	I	See footnote <sup>(2)</sup>		
Series Seed Preferred Shares	(6)	11/03/2021			С			500,000	(6)		(6)	Ordina Share		923,900	3,900 (6)		)	I	See footnote <sup>(3)</sup>		
Series A Preferred Shares	(5)	11/03/2021			С			423,579	(5)		(5)	Ordina Share		477,005	(5)	0		I	See footnote <sup>(4)</sup>		
		f Reporting Person*	<u>.LC</u>																		

(City)	(State)	(Zip)
	of Reporting Person* LIFE SCIENCE	S MASTER FUND
(Last) C/O PERCEPTIV	(First) TE ADVISORS LLC	(Middle)
51 ASTOR PLAC	CE, 10TH FLOOR	
(Street) NEW YORK	NY	10003
(City)	(State)	(Zip)
1. Name and Address  LEV LB Hold	of Reporting Person* ings, <u>LP</u>	
(Last) 51 ASTOR PLAC	(First) CE, 10TH FLOOR	(Middle)
(Street) NEW YORK	NY	10003
(City)	(State)	(Zip)
	of Reporting Person*	Fund, LP
(Last) 51 ASTOR PLAC	(First) CE, 10TH FLOOR	(Middle)
(Street) NEW YORK	NY	10003
(City)	(State)	(Zip)
1. Name and Address C2 Life Science	of Reporting Person*	
(Last) 51 ASTOR PLAC	(First) CE, 10TH FLOOR	(Middle)
(Street) NEW YORK	NY	10003
(City)	(State)	(Zip)
	of Reporting Person* nture Advisors, L	<u>LC</u>
(Last) 51 ASTOR PLAC	(First) CE, 10TH FLOOR	(Middle)
(Street) NEW YORK	NY	10003
(City)	(State)	(Zip)
1. Name and Address <u>LEV LB Hold</u>	of Reporting Person*	
(Last) 51 ASTOR PLAC	(First) CE, 10TH FLOOR	(Middle)
(Street) NEW YORK	NY	10003
(City)	(State)	(Zip)
1. Name and Address EDELMAN JO	of Reporting Person*  OSEPH	
	(First)	(Middle)

(Street) NEW YORK	NY	10003	
(City)	(State)	(Zip)	

## **Explanation of Responses:**

- 1. The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- 2. The securities are directly held by LEV LB Holdings, LP ("LEV LB"). LEV LB Holdings GP, LLC ("LEV LB LLC.") is the manager of LEV LB. Mr. Edelman is the sole member of LEV LB LLC. LEV LB LLC and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- 3. The securities are directly held by Perceptive Xontogeny Venture Fund, LP ("Perceptive Xontogeny"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment advisor to Perceptive Xontogeny and is an affiliate of the Advisor. Joseph Edelman is the managing member of the Advisor. The Venture Advisor, the Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- 4. The securities are directly held by C2 Life Sciences LLC ("C2 Life"). The Advisor serves as the investment advisor to C2 Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- 5. Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.
- 6. Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.
- 7. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$13.25 to \$13.79, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.

## Remarks:

/s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member	11/03/2021
/s/ Joseph Edelman - for Perceptive Life Sciences Master Fund, Ltd., By: Joseph Edelman, its investment manager, By: Joseph Edelman, its managing member	11/03/2021
/s/ Joseph Edelman - for LEV LB Holdings, LP, By: LEV LB Holdings GP, LLC, its general partner, By: Joseph Edelman, its sole member	11/03/2021
/s/ Joseph Edelman - for Perceptive Xontogeny Venture Fund, LP, By: Joseph Edelman, its investment manager, By: Joseph Edelman its managing member	11/03/2021
/s/ Joseph Edelman - for C2 Life Sciences LLC, By: Joseph Edelman, its investment manager, By: Joseph Edelman, its managing member	11/03/2021
/s/ Joseph Edelman - for Perceptive Venture Advisors LLC, By: Joseph Edelman, its managing member	11/03/2021
/s/ Joseph Edelman - for LEV LB Holdings GP, LLC, By: Joseph Edelman, its sole member	11/03/2021
/s/ Joseph Edelman ** Signature of Reporting Person	<u>11/03/2021</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.